CD19 and B-cell chronic lymphocytic leukemia: Additionally, treatment of chronic lymphocytic leukemia (CLL) as another common hematological malignancy was investigated by using the engineered CAR T cell against CD19 or the tyrosine-protein kinase transmembrane receptor [80, 81].